DelveInsight’s “Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Refractory Cough, historical and forecasted epidemiology as well as the Chronic Refractory Cough market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Chronic Refractory Cough market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Refractory Cough Market Forecast
Some of the key facts of the Chronic Refractory Cough Market Report:
-
The Chronic Refractory Cough market size was valued ~USD 8,800 Million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
-
In August 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), has announced that the majority of the 60 planned sites for the Phase 2b CORAL trial have been initiated. The trial, which aims to enroll around 160 patients, will include a sample size re-estimation (SSRE) in the fourth quarter of this year, once 50% of patients are evaluable for the primary endpoint. Barring any adjustments, topline results are expected in the first half of 2025.
-
In March 2024, Nocion Therapeutics, a clinical-stage biopharmaceutical company, has secured $62 million in Series B funding. The company is focused on developing innovative, first-in-class small molecule permanently charged sodium channel blockers (CSCBs), known as nocions, which selectively target and silence activated nociceptors to address conditions involving cough, itch, and pain. The funds will support the advancement of Nocion’s lead candidate, Taplucanium Dry Powder for Inhalation, through a Phase 2b clinical trial in patients with chronic cough.
-
The United States holds the largest market share for Chronic Refractory Cough (CRC) compared to the EU4 (Germany, Italy, France, and Spain), the United Kingdom, and Japan, with an estimated market size of approximately USD 4,500 million in 2023.
-
In 2023, Japan’s market size for Chronic Refractory Cough (CRC) was approximately USD 1,100 million. The market is anticipated to grow further, primarily driven by the introduction of new therapies during the forecast period (2024–2034).
-
The introduction of promising therapies such as MK-7264 (gefapixant), Camlipixant (BLU-5937), Orvepitant Maleate, and others is projected to drive market growth in the coming years, supported by a rise in the diagnosed prevalence of CRC.
-
In 2023, the 12-month prevalence of CC in the 7MM was estimated at approximately 30 million cases. This number is anticipated to grow significantly by 2034, driven by a notable CAGR.
-
In the 7MM, the United States represented nearly 42% of the 12-month prevalent cases of CC, with more than 12 million cases in 2023, a figure expected to grow by 2034.
-
DelveInsight’s analysts estimated that in 2023, the total diagnosed prevalent cases of CRC across the 7MM exceeded 12 million. Among these, the United States had the highest number of diagnosed prevalent cases, followed by Japan. The prevalence of CRC was determined based on the patient pool of CC.
-
In 2023, the gender distribution of CC cases in the US consisted of roughly 40% males and 60% females, with forecasts suggesting an increase by 2034.
-
In 2023, Germany had the highest number of diagnosed prevalent CRC cases among European countries, with 1.3 million cases, followed by the UK with 1 million cases. In contrast, Spain had the lowest number of diagnosed CRC cases among the EU4 and the UK.
-
Key Chronic Refractory Cough Companies: Merck & Co, GSK, NeRRe Therapeutics, Trevi Therapeutics, Beijing Tide Pharmaceutical, Bellus Health Inc., Axalbion, Jiangsu Hansoh Pharma, Melius Pharma AB, Genentech, Inc., and others
-
Key Chronic Refractory Cough Therapies: MK-7264 (gefapixant), Camlipixant, Orvepitant Maleate, AX-8, Nalbuphine ER, TCR1672 tablet, BLU-5937, HS-10383, ME-015 (Suplatast Tosilate), GDC-6599, and others
-
The Chronic Refractory Cough epidemiology based on gender analyzed that it can be concluded that CRC is more common in women as compared to men
-
The Chronic Refractory Cough market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Refractory Cough pipeline products will significantly revolutionize the Chronic Refractory Cough market dynamics.
Chronic Refractory Cough Overview
A reflex action with some elements of intentional control is coughing. It is a component of the somatosensory system, which also includes visceral sensation, a reflexive motor response, and related behavioural reactions. Additionally, it can be acute (lasting less than three weeks), subacute (lasting between three and eight weeks), or chronic (lasting longer than eight weeks) in nature can be a sign of several common respiratory disorders.
Get a Free sample for the Chronic Refractory Cough Market Report
https://www.delveinsight.com/report-store/chronic-refractory-cough-market
Chronic Refractory Cough Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Chronic Refractory Cough Epidemiology Segmentation:
The Chronic Refractory Cough market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
-
Total Prevalence of Chronic Refractory Cough
-
Prevalent Cases of Chronic Refractory Cough by severity
-
Gender-specific Prevalence of Chronic Refractory Cough
-
Diagnosed Cases of Episodic and Chronic Chronic Refractory Cough
Download the report to understand which factors are driving Chronic Refractory Cough epidemiology trends @ Chronic Refractory Cough Epidemiology Forecast
Chronic Refractory Cough Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Refractory Cough market or expected to get launched during the study period. The analysis covers Chronic Refractory Cough market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Refractory Cough Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Chronic Refractory Cough Therapies and Key Companies
-
MK-7264 (gefapixant): Merck & Co
-
Camlipixant: GSK
-
Orvepitant Maleate: NeRRe Therapeutics
-
AX-8: Axalbion
-
Nalbuphine ER: Trevi Therapeutics
-
TCR1672 tablet: Beijing Tide Pharmaceutical
-
BLU-5937: Bellus Health Inc.
-
HS-10383: Jiangsu Hansoh Pharma
-
ME-015 (Suplatast Tosilate): Melius Pharma AB
-
GDC-6599: Genentech, Inc.
Discover more about therapies set to grab major Chronic Refractory Cough market share @ Chronic Refractory Cough Treatment Market
Chronic Refractory Cough Market Strengths
-
Growing research and development in the area may increase the probability of development of potential effective therapy for CRC.
-
There is a significant increase in the prevalent population of CRC which will drive the market in the long run.
Chronic Refractory Cough Market Opportunities
-
There is a lack of efficacious medication or therapy which provides an extensive market opportunity for the emerging companies to accelerate and dominate the CRC market.
-
Increased public awareness creates a lucrative opportunity for innovation of therapeutics to drive CRC market.
Scope of the Chronic Refractory Cough Market Report
-
Study Period: 2020–2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Chronic Refractory Cough Companies: Merck & Co, GSK, NeRRe Therapeutics, Trevi Therapeutics, Beijing Tide Pharmaceutical, Bellus Health Inc., Axalbion, Jiangsu Hansoh Pharma, Melius Pharma AB, Genentech, Inc., and others
-
Key Chronic Refractory Cough Therapies: MK-7264 (gefapixant), Camlipixant, Orvepitant Maleate, AX-8, Nalbuphine ER, TCR1672 tablet, BLU-5937, HS-10383, ME-015 (Suplatast Tosilate), GDC-6599, and others
-
Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies
-
Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Chronic Refractory Cough Unmet Needs, KOL’s views, Analyst’s views, Chronic Refractory Cough Market Access and Reimbursement
To know more about Chronic Refractory Cough companies working in the treatment market, visit @ Chronic Refractory Cough Clinical Trials and Therapeutic Assessment
Table of Contents
1. Chronic Refractory Cough Market Report Introduction
2. Executive Summary for Chronic Refractory Cough
3. SWOT analysis of Chronic Refractory Cough
4. Chronic Refractory Cough Patient Share (%) Overview at a Glance
5. Chronic Refractory Cough Market Overview at a Glance
6. Chronic Refractory Cough Disease Background and Overview
7. Chronic Refractory Cough Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Refractory Cough
9. Chronic Refractory Cough Current Treatment and Medical Practices
10. Chronic Refractory Cough Unmet Needs
11. Chronic Refractory Cough Emerging Therapies
12. Chronic Refractory Cough Market Outlook
13. Country-Wise Chronic Refractory Cough Market Analysis (2020–2034)
14. Chronic Refractory Cough Market Access and Reimbursement of Therapies
15. Chronic Refractory Cough Market Drivers
16. Chronic Refractory Cough Market Barriers
17. Chronic Refractory Cough Appendix
18. Chronic Refractory Cough Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/